CTRI/2011/091/000206招募中4 期
A Post-Marketing Surveillance Study to assess the safety and efficacy of Cetuximab plus Radiotherapy (RT) in Locally Advanced Squamous Cell Carcinoma of Head & Neck (LA SCCHN)
Merck Specialities Pvt Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •The study inclusion & exclusion criteria are as per the local SPC: Cetuximab in combination with RT is indicated for the treatment of patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
排除标准
- •For the prescription of Cetuximab (Erbitux®) the product label approved by India Health Authority should also be followed strictly in terms of patient eligibility.
研究者
相似试验
已完成
4 期
A study of Pregabalin IP 75 mg and Nortriptyline 10 mg Tablets in patients with diabetic peripheral neuropathyCTRI/2022/02/040438Micro Labs Limited203
尚未招募
4 期
Post marketing surveillance study of Pitavastatin for evaluation of its safety and efficacy in patients with diabetes and high cholesterolCTRI/2013/05/003686Cadila Healthcare500
已完成
4 期
Post-marketing SurveillanceStudy in patients prescribed with Darbepoetin alfaCTRI/2017/04/008338Hetero Drugs Limited503
进行中（未招募）
1 期
Study To Evaluate The Safety And Efficacy Of Vfend® IV in Korean patientsEUCTR2017-000197-11-Outside-EU/EEAPfizer Inc.400
进行中（未招募）
不适用
reactogenicity and safety of Vaxem™HibMeningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.EUCTR2014-005203-24-Outside-EU/EEAovartis Vaccines and Diagnostics750